New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
GlobeStar Therapeutics Corporation
GSTC
Shape
US Flag

PNK

Unprofitable

EPS improving

Unprofitable

EPS improving

496444

Biotechnology

0.00USD
0.00 ( 0.00%)
Market Open
favorite-chart

Relative Strenght

favorite-chart

Volume Buzz

316%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

100%
OverviewChart

Quote Panel

Shape
Updated October 9, 2024
1W -20.00 % 1M -20.00 % 3M -60.00 % 1Y -85.19 %

Key Metrics

Shape

  • Market Cap

    496444

  • Shares Outstanding

    1.24B

  • Share in Float

    1.22B

  • Dividende

    0

  • Earning Date

    No Data

  • Price Target

    0.0004

  • Average Volume

    7.72M

  • Beta

    1.55

  • Range

    2.0E-4-0.0033

  • Industry

    Biotechnology

  • Website

    https://www.globestarthera.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

0.00x

P/S Ratio

-0.31x

P/B Ratio

-0.2

Debt/Equity

0.0%

Net Margin

$0.0

EPS

How GSTC compares to sector?

P/E Ratio

GSTC

0x

MYMX 0x
PKTX -13x
RSPI -1x
SILO -1x
CRPOF -3x

Relative Strength

Shape

GSTC

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

No Data Available

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q4.21

arrow
arrow

N/A

-0.00
vs -0.00

Q1.22

arrow
arrow

N/A

NA
vs -0.00

Q2.22

arrow
arrow

N/A

-0.00
vs -0.01

Q3.22

arrow
arrow

N/A

NA
vs NA

Q4.22

arrow
arrow

N/A

-0.00
vs -0.00

Q1.23

arrow
arrow

N/A

NA
vs NA

Q2.23

arrow
arrow

N/A

-0.00
vs -0.00

Q3.23

arrow
arrow

N/A

NA
vs NA

Q4.23

arrow
arrow

+100%

NA
vs -0.00

Q1.24

arrow
arrow

N/A

NA
vs NA

Sales GrowthShape

status-upYoY

Current

Estimates

Q4.21

arrow
arrow

NA

NA  vs NA

Q1.22

arrow
arrow

NA

NA  vs NA

Q2.22

arrow
arrow

NA

NA  vs NA

Q3.22

arrow
arrow

-100%

NA  vs 4.8K

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

NA  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q2.22

arrow
arrow

+16%

0.16
vs 0.64

Q3.22

arrow
arrow

+26%

0.26
vs 0.16

Q4.22

arrow
arrow

+14%

0.14
vs 0.26

Q1.23

arrow
arrow

+13%

0.13
vs 0.14

Q2.23

arrow
arrow

+100%

1
vs 0.13

Q3.23

arrow
arrow

+24%

0.24
vs 1

Q4.23

arrow
arrow

+11%

0.11
vs 0.24

Q1.24

arrow
arrow

+12%

0.12
vs 0.11

Institutionnal OwnershipShape

status-upQoQ

Q4.21

arrow
arrow

2

2
vs 3

-33%

Q1.22

arrow
arrow

2

2
vs 2

NA

Q4.22

arrow
arrow

2

2
vs NA

NA

Q1.23

arrow
arrow

1

1
vs 2

-50%

Q2.23

arrow
arrow

1

1
vs 1

NA

Q3.23

arrow
arrow

1

1
vs 1

NA

Q4.23

arrow
arrow

1

1
vs 1

NA

Q1.24

arrow
arrow

1

1
vs 1

NA

Earnings Growth

Latest News

GSTC

accesswire.com

6 hours ago

Globestar Therapeutics Enters into Definitive Agreement with SMI Healthcare to Manage Clinical Trial, Regulatory Filings, Manufacturing and Sales in MEA Region for Multiple Sclerosis Treatment
GSTC

accesswire.com

8 hours ago

Globestar Therapeutics Update on Project Amethyst(TM) and Recent Financials
GSTC

accesswire.com

8 hours ago

GlobeStar Therapeutics Enters Into Definitive Agreement With Advanced Innovative Partners To Develop Clinical Studies and Strategies for Multiple Sclerosis Treatment
GSTC

accesswire.com

8 hours ago

GlobeStar Therapeutics Corporation Has Been Upgraded to the QB Tier on OTC Markets
GSTC

accesswire.com

9 hours ago

GlobeStar Therapeutics Corporation Additional Progress Toward A U.S.-Based Clinical Trial.
GSTC

accesswire.com

16 hours ago

GlobeStar Therapeutics Corporation Files New 8K Statement Focused On Progress, Market Acceptance, And A Potential Game-Changing Drug For Multiple Sclerosis

New Feature Coming Soon, Stay Tuned!

ShapeShape